Intratumoral heterogeneity, error-prone, subjective scoring methods, and limited tissue samples present challenges for reliable quantification of PD-L1 by IHC in NSCLC and lead to a lack of clinical test sensitivity [8,9,37,38]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.